A Phase 1/2 interventional study of VAD044 Part I and VAD044 Part II in Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by Vaderis Therapeutics AG. Active, not recruiting at 7 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Vaderis Therapeutics AG · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Part I: The purpose of this Phase 1b proof of concept study, randomised, placebo controlled, double blind, multicentre study is to asssess safety and efficacy of 2 doses of VAD044 in adult HHT patients.
Part II: The purpose of this open-label extension following the completion of the randomised double blind treatment and follow-up period (Part I of the study) is to assess the long-term safetty, tolerability and efficacy of VAD044 in adult HHT patients.
Part I: After being informed about the study and the potential risks, all patients giving written informed consent will undergo a two months screening and observation period to determine eligibility for study entry. At Day 0, patients who meet the eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 1:1:1 ratio to 30mg VAD044 (once daily), 40 mg (once daily) or placebo (once daily).
Part II: Patients who have completed the study Part I can participate in the open-label extension study (Part II).The patients can roll over immediately after last visit of the Part I or at any time at their convenience and according to their availability, but within a timeframe no longer than 8 months after the last visit (visit 12) of the part I. All patients in Part II will receive 30 mg of VAD044 once daily for the first 4 weeks afterwards the daily dose can be increased to 40 mg daily for up to 36 months.
106 studies on the registry are indexed under Telangiectasia, Hereditary Hemorrhagic; 24 are open to participants now.
This study's enrollment of 75 is above the median of 33 across 61 interventional studies indexed under Telangiectasia, Hereditary Hemorrhagic.
Browse Telangiectasia, Hereditary Hemorrhagic studies →Vaderis Therapeutics AG is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
For Part I of the study:
Inclusion Criteria:
Exclusion Criteria:
Fort Part II of the study:
Inclusion Criteria:
Exclusion Criteria:
- Same as in Part I.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 mg VAD044
Drug: VAD044 Part I · Drug: VAD044 Part II
40 mg VAD044
Drug: VAD044 Part I · Drug: VAD044 Part II
Placebo
Drug: VAD044 Part I
capsules to be taken once daily for 12 weeks
Also known as: VAD044 L-Tartrate gelatin capsules
capsules to be taken once daily for 36 months
Also known as: VAD044 L-Tartrate gelatin capsules
Part I: Safety and Tolerability
Type and severity of Adverse Events (AEs)
Time frame: 12 weeks
Part II: Safety and Tolerability
Type and severity of Adverse Events (AEs)
Time frame: 36 months
Part I: Change in Epistaxis episodes
The number of Epistaxis episodes
Time frame: 12 weeks
Part I: Change in Epistaxis duration
Epistaxis duration
Time frame: 12 weeks
Part I: Change in Epistaxis intensity
Epistaxis flow intensity
Time frame: 12 weeks
Part I: Change in Epistaxis Severity Score (ESS)
ESS used to evaluate the current severity of HHT patient nosebleeds (typically in the last three months) and can help health care providers to evaluate how a patient is responding to treatment. This score ranges from 0-10 and is automatically calculated after answering six simple questions. The higher the score the more severe.
Time frame: 12 weeks
Part I: Change in Haemoglobin
Haemoglobin
Time frame: 12 weeks
Part I: Change Ferritin
Ferritin
Time frame: 12 weeks
Part I: Change in blood Transferrin saturation level
Transferrin saturation level
Time frame: 12 weeks
Part I: Change in Iron supplementation needs
Iron supplementation needs
Time frame: 12 weeks
Part I: Change Blood tranfusions requirements
Blood tranfusions requirements
Time frame: 12 weeks
Part I: Change in the Nasal Outcome for Epistaxis in Hereditary Hemorrhagic Telangiectasia score
The Nasal Outcome for Epistaxis in Hereditary Hemorrhagic Telangiectasia (NOSE HHT questionnaire) wil be used to measure physical, social and emotional impacts of epistaxis. It is a 29-items questionnaire using a Likert scale. A higher score indicates a worse outcome
Time frame: 12 weeks
Part I: Quality of Life Scale SF-12
The SF-12 Quality of Life Scale is a scale to evaluate quality of life using 12 questions. In the SF-12, physical (SF12-PCS) and mental (SF12-MCS) component summary scores are calculated as sub-dimensions. The total score of the physical and mental component summary of the scale varies between 0-100. An increase in the score indicates well-being, and a decrease indicates a state of disability.
Time frame: 12 weeks
Part I: Plasma concentration of VAD044
Plasma concentration of VAD044
Time frame: 12 weeks
Part I: Maximum concentration (Cmax) of VAD04
Maximum concentration (Cmax) of VAD044
Time frame: 12 weeks
Part I: Time of maximum concentration (Tmax) of VAD044
Time of maximum concentration (Tmax) of VAD044
Time frame: 12 weeks
Part I: Area under the curve (exposure to drug) during 24 hours (AUC0-24h) of VAD044
Area under the curve (exposure to drug) during 24 hours (AUC0-24h) of VAD044
Time frame: 12 weeks
Part I: Trough concentration (Ctrough) of VAD044
Trough concentration (Ctrough) of VAD044
Time frame: 12 weeks
Part I: Pharmacodynamics (PD) of VAD044
PRP assay to measure the levels of pAKT in the blood in a subset of patients
Time frame: 12 weeks
Part II: Change in The number of Epistaxis episodes
The number of Epistaxis episodes
Time frame: 24 months
Part II: Change in Epistaxis duration
Epistaxis duration
Time frame: 24 months
Part II: Change in Epistaxis flow intensity
Epistaxis flow intensity
Time frame: 24 months
Part II: Change in Epistaxis Severity Score (ESS)
ESS used to evaluate the current severity of HHT patient nosebleeds (typically in the last three months) and can help health care providers to evaluate how a patient is responding to treatment. This score ranges from 0-10 and is automatically calculated after answering six simple questions. The higher the score the more severe.
Time frame: 24 months
Part II: Change in Haemoglobin
Haemoglobin
Time frame: 24 months
Part II: Change in Ferritin
Ferritin
Time frame: 24 months
Part II: Change in Transferrin saturation level
Transferrin saturation level
Time frame: 24 months
Part II: Change in Iron supplementation needs
Iron supplementation needs
Time frame: 24 months
Part II: Change in blood tranfusions requirements
blood tranfusions requirements
Time frame: 24 months
Part II: Quality of Life Scale SF-12
The SF-12 Quality of Life Scale is a scale to evaluate quality of life using 12 questions. In the SF-12, physical (SF12-PCS) and mental (SF12-MCS) component summary scores are calculated as sub-dimensions. The total score of the physical and mental component summary of the scale varies between 0-100. An increase in the score indicates well-being, and a decrease indicates a state of disability.
Time frame: 24 months
Started Jul 2022 (actual). Primary completion is estimated for Jan 2027, 54 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Engasertib
Telangiectasia, Hereditary Hemorrhagic →
Vaderis Therapeutics AG